Abstract: The manufacturing ordering assistance apparatus, method and program according to the first embodiment of the present embodiment are configured such that the manufacturing ordering assistance apparatus capable of transmitting data by way of a network between a first terminal used by a product manufacturer and second terminals used by parts manufacturers acquires design information of a product from the first terminal; identifies information relating to parts from the acquired design information; generates, for the respective parts, parts manufacturing information necessary to manufacture the parts based on the identified information relating to the parts; and selects a parts manufacturer as an order recipient for the respective parts based on the generated parts manufacturing information and information relating to manufacturing capacities of the parts manufacturers.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: Provided is an Fe—Ni—Cr alloy that has excellent surface characteristics and enables formation of a blackened coating having excellent blackening characteristics and peeling resistance. The Fe—Ni—Cr alloy has a chemical composition containing, by mass %, C, Si, Mn, P, S, Cr, Ni, Mo, Co, Cu, N, Ti, Al, O, and H, the balance being Fe and inevitable impurities, and satisfying formulae (1) to (4): (1) T1=11×[% N]+0.1; (2) T2=?39×[% N]?1.0; (3) A1=7.5×[% N]+0.1; (4) A2=?42.5×[% N]+1.0, where [% M] represents content (mass %) of element M in the alloy, and T1, T2, A1, and A2 satisfy relationships T1<[% Ti]<T2 and A1<[% A1]<A2.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: Provided is an Fe—Ni—Cr alloy that has excellent surface characteristics and enables formation of a blackened coating having excellent blackening characteristics and peeling resistance. The Fe—Ni—Cr alloy has a chemical composition containing, by mass %, C, Si, Mn, P, S, Cr, Ni, Mo, Co, Cu, N, Ti, Al, O, and H, the balance being Fe and inevitable impurities, and satisfying formulae (1) to (4): (1) T1=11×[% N]+0.1; (2) T2=?39×[% N]?1.0; (3) A1=7.5×[% N]+0.1; (4) A2=?42.5×[% N]+1.0, where [% M] represents content (mass %) of element M in the alloy, and T1, T2, A1, and A2 satisfy relationships T1<[% Ti]<T2 and A1<[% A1]<A2.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: An austenitic Fe—Ni—Cr alloy comprises C: 0.005˜0.03 mass %, Si: 0.17˜1.0 mass %, Mn: not more than 2.0 mass %, P: not more than 0.030 mass %, S: not more than 0.0015 mass %, Cr: 18˜28 mass %, Ni: 21.5˜32 mass %, Mo: 0.10˜2.8 mass %, Co: 0.05˜2.0 mass %, Cu: less than 0.25 mass %, N: not more than 0.018 mass %, Al: 0.10˜1.0 mass %, Ti: 0.10˜1.0 mass %, Zr: 0.01˜0.5 mass %, and the balance being Fe and inevitable impurities; wherein Cr, Mo, N and Cu satisfy PRE=Cr+3.3×Mo+16×N?20.0 and PREH=411-13.2×Cr-5.8×Mo+0.1×Mo2+1.2×Cu?145.0 and wherein Al, Ti, and Zr satisfy 0.5?Al+Ti+1.5×Zr?1.5, and has an excellent corrosion resistance in air or under a wet environment even at a surface state having an oxide film formed by an intermediate heat treatment.

Abstract: High-Mn austenitic stainless steels having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.0028 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass % with the balance being Fe and inevitable impurities, provided that these components are contained so that ? cal represented by the following equation is not more than 5.5%: ? cal (mass %)=(Cr+0.48Si)?(Ni+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7, wherein each element symbol in the equation is a content of the respective element (mass %), and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: An austenitic Fe—Ni—Cr alloy comprises C: 0.005˜0.03 mass %, Si: 0.17˜4.0 mass %, Mn: not more than 2.0 mass %, P: not more than 0.030 mass %, S: not more than 0.0015 mass %, Cr: 18˜28 mass %, Ni: 21.5˜32 mass %, Mo: 0.10˜2.8 mass %, Co: 0.05˜2.0 mass %, Cu: less than 0.25 mass %, N: not more than 0.018 mass %, Al: 0.10˜4.0 mass %, Ti: 0.10˜1.0 mass %, Zr: 0.01˜0.5 mass %, and the balance being Fe and inevitable impurities; wherein Cr, Mo, N and Cu satisfy PRE=Cr+3.3×Mo+16×N?20.0 and PREH=411-13.2×Cr-5.8×Mo+0.1×Mo2+1.2×Cu?145.0 and wherein Al, Ti, and Zr satisfy 0.5?Al+Ti+1.5×Zr?1.5, and has an excellent corrosion resistance in air or under a wet environment even at a surface state having an oxide film formed by an intermediate heat treatment.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: High-Mn austenitic stainless steels having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.0028 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass % with the balance being Fe and inevitable impurities, provided that these components are contained so that ? cal represented by the following equation is not more than 5.5%: ? cal (mass %)=(Cr+0.48Si)?(Ni+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7, wherein each element symbol in the equation is a content of the respective element (mass %), and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: High-Mn austenitic stainless steels having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.0028 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass % with the balance being Fe and inevitable impurities, provided that these components are contained so that ? cal represented by the following equation is not more than 5.5%: ? cal (mass %)=(Cr+0.48Si)?(Ni+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7, wherein each element symbol in the equation is a content of the respective element (mass %), and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: As a stainless steel for a metal part for clothing ornament capable of working into a complicated form part and having such nonmagnetic properties that the worked part can cope with the detection through needle detecting device is provided a high-Mn austenitic stainless steel having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.03 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass %, provided that these components are contained so that ? cal (mass %) represented by the following equation (1) is not more than 5.5 mass %: ? cal (mass %)=(Cr+0.48Si+1.21Mo+2.2(V+Ti)+0.15Nb)?(Ni+0.47Cu+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7??(1) and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: An austenitic Fe—Ni—Cr alloy comprises C: 0.005˜0.03 mass %, Si: 0.15˜1.0 mass %, Mn: not more than 2.0 mass %, P: not more than 0.030 mass %, S: not more than 0.002 mass %, Cr: 18˜28 mass %, Ni: 20˜38 mass %, Mo: 0.10˜3 mass %, Co: 0.05˜2.0 mass %, Cu: less than 0.25 mass %, N: not more than 0.02 mass %, provided that PRE=Cr+3.3×Mo+16×N?20.0 and PREH=411?13.2×Cr?5.8×Mo+0.1×Mo2+1.2×Cu?145.0 (wherein each element symbol represents a content (mass %) of each element) and has an excellent corrosion resistance in air or under a wet environment even at a surface state having an oxide film formed by a intermediate heat treatment on the way of the production process.

Abstract: As a stainless steel for a metal part for clothing ornament capable of working into a complicated form part and having such nonmagnetic properties that the worked part can cope with the detection through needle detecting device is provided a high-Mn austenitic stainless steel having a chemical composition comprising C: 0.02-0.12 mass %, Si: 0.05-1.5 mass %, Mn: 10.0-22.0 mass %, S: not more than 0.03 mass %, Ni: 4.0-12.0 mass %, Cr: 14.0-25.0 mass % and N: 0.07-0.17 mass %, provided that these components are contained so that ? cal (mass %) represented by the following equation (1) is not more than 5.5 mass %: ? cal (mass %)=(Cr+0.48Si+1.21Mo+2.2(V+Ti)+0.15Nb)?(Ni+0.47Cu+0.11Mn?0.0101Mn2+26.4C+20.1N)?4.7??(1) and having a magnetic permeability of not more than 1.003 under a magnetic field of 200 kA/m.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.

Abstract: A magnetostrictive torque sensor that detects a torque of a rotating shaft and/or a stationary shaft by using a magnetostriction inverse effect that occurs on a shaft surface, the magnetostrictive torque sensor includes a first detection coil, a second detection coil, a first oscillation circuit, a second oscillation circuit, a first direction magnetic permeability detector, a second direction magnetic permeability detector, and a torque detector.

Abstract: Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1, EFHC1 agonists, or EFHC1 analogs are provided. Compositions and methods for diagnosis or treatment of epilepsy disease with EFHC1a, EFHC1a agonists, or EFHC1a analogs are provided.